ARCHIVES

GPC Biotech’s Satraplatin Fails To Extend Survival In Hormone-Refractory Prostate Cancer.

This article is from The Cancer Letter archive.

Vol. 33 No. 40 | November 2, 2007

Download PDF Visit The Full Archive

Related Articles

Anil Potti Reprimanded by North Carolina Licensure Board

December 9, 2011

IL13-PE38 Looks Promising In Early Tests Against Gioma

September 27, 2002

Einhorn Sees More Results Coming Similar to Big Successes in Testicular Cancer

May 15, 1981

NINDS Awards Grants For Brain Tumor Centers

December 11, 1992

State Cancer Incidence Report Published by NCI, CDC

November 22, 2002

In Phase II Study, NKTR-102 Shows Objective Response

January 28, 2011